Exciting BRAF results coming at #ESMO26 ! Important updates ahead. Stay tuned! @SandraOrtizCua1
427 views · 8 likes · 5 reposts · 0 replies
STARBOARD phase 3: A randomized, double-blind study of first-line (1L) encorafenib (enco), binimetinib (bini), and pembrolizumab (pembro) vs placebo (pbo) and pembro for unresectable locally advanced or metastatic BRAF V600-mutant melanoma
https://esmocongress.esmo.orgImpact of BRAF V600K mutation in patients with resectable stage III melanoma: A subgroup analysis of the NADINA trial
https://esmocongress.esmo.orgEncorafenib plus cetuximab (EC) beyond progression in combination with FOLFIRI in BRAF V600E metastatic colorectal cancer (mCRC) patients (pts) progressing on EC: Results from the ECLYPse phase II trial
https://esmocongress.esmo.orgExtended circulating tumor DNA (ctDNA) sequencing to optimize the selection between anti-EGFR rechallenge and other later lines in patients with RAS/BRAF wild-type metastatic colorectal cancer
https://esmocongress.esmo.org- **标题 / Title：** Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC
https://esmocongress.esmo.org- **标题 / Title：** Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.
https://esmocongress.esmo.org#ESMO26 starts today ! 🎯 Do not miss the upcoming presentations on #BRAF-mutant NSCLC. @C_Ricordel @dplanchard @AurelieSwalduz @rohit_gosain @OncBrothers @IFCTlung @OncoAlert @BrafBombers #BOLEROConsortium #NSCLC #LCSM在 X 查看被引用的帖子
Source: d.planchard · x.com